MOTS-c (mitochondrial open reading frame of the twelve-S ribosomal RNA type-c) is a sixteen–amino-acid mitochondrial-derived peptide that has become one of the most studied entries in the emerging field of mitochondrial signaling. Unlike the classical peptides encoded by the nuclear genome, MOTS-c is transcribed from a short open reading frame nested inside the mitochondrial 12S ribosomal RNA gene — a discovery that reframed the mitochondrion as an active endocrine and regulatory hub rather than a passive power plant. This review surveys the peptide's biology, its proposed mechanism through the folate cycle and AMP-activated protein kinase (AMPK), and the preclinical literature to date. All content is provided strictly for research reference.
What is MOTS-c? MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded within the 12S rRNA region of mitochondrial DNA. In preclinical models it has been reported to inhibit the folate cycle, raise intracellular AICAR, and activate AMPK — a metabolic-stress pathway associated with glucose handling and an exercise-mimetic phenotype. It remains a research-use-only compound with no completed human efficacy trials.
Key research findings at a glance
- Identified in 2015 as the founding "metabolic" member of the mitochondrial-derived peptide (MDP) family.
- Proposed mechanism: folate-cycle inhibition → AICAR accumulation → AMPK activation.
- Reported in rodent models to influence glucose tolerance, diet-induced obesity, and skeletal-muscle metabolism.
- Functions as a retrograde signal, translocating to the nucleus under metabolic stress.
- Evidence remains preclinical; no published human efficacy trials.
Introduction: a peptide written in the mitochondrial genome
For most of the twentieth century, the mitochondrial genome was understood to encode only thirteen proteins, all subunits of the oxidative-phosphorylation machinery. The identification of MOTS-c by Lee and colleagues in 2015 challenged that view [1]. Working from the observation that short open reading frames within mitochondrial ribosomal RNA genes could be translated, the group isolated a sixteen-residue peptide and reported that its administration in mice was associated with resistance to high-fat-diet–induced obesity and improved insulin sensitivity [1]. The finding established a second class of functional molecule emerging from mitochondrial DNA and helped consolidate the concept of the mitochondrial-derived peptide, or MDP.
What distinguishes MOTS-c from nuclear-encoded signaling peptides is not only its origin but its proposed role as a communicator of mitochondrial metabolic state to the rest of the cell. Where classical hormones broadcast systemic signals, MOTS-c has been investigated as a molecule that reports on — and helps adjust to — cellular energy stress. The sections that follow describe the biological system it acts within, the folate–AICAR–AMPK axis that underlies its reported effects, and the preclinical evidence organized by research domain.
Biological background: mitochondrial-derived peptides
Mitochondrial-derived peptides are small peptides encoded within the mitochondrial genome rather than the nucleus. Two families have received the most attention: humanin, a twenty-four–residue cytoprotective peptide encoded in the 16S rRNA gene, and MOTS-c, encoded in the 12S rRNA gene. Both are thought to participate in a bidirectional dialogue between the mitochondrion and the nucleus, a phenomenon researchers describe as retrograde signaling. In the case of MOTS-c, that dialogue is proposed to be metabolic: the peptide is studied as a sensor and modulator of the balance between energy supply and demand.
The concept matters because it positions the mitochondrion as more than a target of cellular regulation — it becomes a source of it. Circulating MOTS-c has been detected in human plasma, and observational studies have reported that acute exercise is associated with increased MOTS-c in skeletal muscle and circulation [4]. These endogenous fluctuations form the backdrop against which exogenous MOTS-c has been examined in laboratory models. It is important to distinguish, throughout, between a naturally occurring biomarker that rises with physical activity and a synthetic peptide administered experimentally; the two are not interchangeable, and the research literature treats them separately.
Structure and mechanism of action
MOTS-c is a linear peptide of sixteen amino acids. Its comparatively small size and the absence of extensive post-translational modification make it tractable for synthesis, which has facilitated the preclinical work described below. Mechanistically, the most developed model centers on the one-carbon folate cycle.
In the framework proposed by Lee and colleagues and elaborated in subsequent work, MOTS-c is reported to inhibit steps in the folate cycle, thereby restricting de novo purine biosynthesis [1]. A downstream consequence is the intracellular accumulation of 5-aminoimidazole-4-carboxamide ribonucleotide, or AICAR — a well-characterized endogenous activator of AMP-activated protein kinase. AMPK, in turn, functions as a master sensor of cellular energy charge: when activated, it is associated with increased glucose uptake through GLUT4 translocation, enhanced fatty-acid oxidation, and a general shift toward catabolic, energy-generating pathways. This folate → AICAR → AMPK cascade is the mechanistic spine of the "exercise-mimetic" language that surrounds MOTS-c in the research community.
Retrograde nuclear signaling. Beyond its cytoplasmic role, MOTS-c has been reported to translocate from the mitochondria to the nucleus under conditions of metabolic stress such as glucose restriction or oxidative challenge [3]. Once in the nucleus, it has been observed to associate with stress-responsive transcription factors and antioxidant response elements, influencing the expression of genes involved in cellular stress resistance [3]. This dual localization — cytoplasmic metabolic modulation and nuclear transcriptional regulation — is a defining feature of the peptide and separates it mechanistically from conventional growth-factor or secretagogue peptides.
Evidence by research domain
The MOTS-c literature is almost entirely preclinical, drawn from rodent models and in vitro systems. The table below summarizes the principal research domains, the models typically used, the reported findings, and an assessment of evidence maturity.
| Research domain | Typical models | Reported findings | Evidence maturity |
|---|---|---|---|
| Glucose metabolism | High-fat-diet mice; cultured myotubes | Improved glucose tolerance and insulin sensitivity; GLUT4 translocation [1] | Preclinical, multiple labs |
| Body composition | Diet-induced obese mice | Attenuated weight gain and adiposity in rodents [1] | Preclinical |
| Skeletal muscle / exercise | Aged mice; human exercise cohorts (observational) | Reported improvements in physical performance; endogenous rise after exercise [4] | Preclinical + human observational |
| Bone metabolism | Ovariectomized mice; osteoblast/osteoclast cultures | Promotion of osteoblast differentiation; attenuated bone loss via AMPK/RANKL pathways [2] | Preclinical, emerging |
| Cardiac function | Transverse aortic constriction mice | Attenuated cardiac dysfunction; reduced inflammatory signaling [2] | Preclinical, early |
Metabolic and glucose-handling research
The foundational metabolic observations come from the original 2015 report, in which MOTS-c administration was associated with prevention of diet-induced insulin resistance in mice and with enhanced glucose uptake in cultured muscle cells [1]. Subsequent studies have examined lipid and organic-acid pathways that are typically dysregulated in type-2-diabetes models, reporting patterns consistent with AMPK-mediated metabolic reprogramming. These findings are the most replicated within the MOTS-c literature, though they remain confined to animal and cell systems.
Skeletal muscle, aging, and the exercise-mimetic hypothesis
A second domain concerns physical performance. In aged-mouse studies, exogenous MOTS-c has been associated with improvements in treadmill endurance and grip strength [4]. In parallel, human observational work has documented that MOTS-c levels in skeletal muscle and circulation rise following acute exercise [4]. The convergence of these observations underlies the popular framing of MOTS-c as an "exercise mimetic," but the research community is careful to distinguish an endogenous biomarker that tracks activity from a therapeutic effect of administered peptide — a gap that no human trial has yet bridged.
Bone and cardiac research
More recent preclinical work has extended MOTS-c research into skeletal and cardiovascular systems. In ovariectomized-mouse models of bone loss, MOTS-c has been reported to promote osteoblast proliferation and mineralization while restraining osteoclastogenesis, with proposed involvement of AMPK and RANKL signaling [2]. In a transverse aortic constriction model, subcutaneous MOTS-c was reported to attenuate cardiac dysfunction and inflammatory signaling [2]. These are early findings from small cohorts and should be read as hypothesis-generating.
The mitochondrial-derived peptide family
MOTS-c is best understood alongside its sibling peptides. The mitochondrial-derived peptide family shares a common origin in mitochondrial ribosomal RNA genes but diverges sharply in reported function. The comparison below situates MOTS-c within that family and links to companion research reviews on this site.
| Peptide | Length | Encoding region | Primary research focus |
|---|---|---|---|
| MOTS-c | 16 aa | 12S rRNA | Metabolism, AMPK, exercise mimicry |
| Humanin | 24 aa | 16S rRNA | Cytoprotection, apoptosis modulation, neuroprotection |
| SHLPs 1–6 | Variable | 16S rRNA | Metabolic and cytoprotective signaling (early research) |
Whereas MOTS-c is studied chiefly as a metabolic regulator, its better-known relative humanin is investigated primarily for apoptosis modulation and neuroprotection; readers can explore that biology in our companion humanin research review. Both peptides intersect with pathways covered in our reviews of metabolic compounds and cellular-stress signaling, making the MDP family a coherent cluster for laboratory study.
Limitations and research considerations
Model dependence. The overwhelming majority of MOTS-c findings derive from rodents and cultured cells. Species differences in metabolism, peptide stability, and receptor context mean that these observations may not translate to other systems.
No human efficacy trials. As of this review, no completed human efficacy trials establish the safety or benefit of administered MOTS-c for any endpoint. The human data that exists is observational, characterizing endogenous peptide levels rather than the effects of exogenous administration.
Stability and delivery. Like many small peptides, MOTS-c is subject to rapid clearance, and the pharmacokinetics of exogenous preparations in laboratory settings are incompletely characterized. This complicates dose–response interpretation across studies.
Sourcing and identity. Material labeled as MOTS-c varies in purity and sequence fidelity. Analytical verification — mass spectrometry and high-performance liquid chromatography — is essential before any research use, and certificates of analysis should be scrutinized rather than assumed.
Where to source for research
MOTS-c intended for laboratory investigation should be obtained only from suppliers that provide third-party analytical documentation, transparent certificates of analysis, and clear research-use-only labeling. Several suppliers in this space publish batch-level testing data. Short Chain Aminos maintains published analytical documentation for its research catalog, and comparable material is listed by BioPep, Catalyst Research, and Apex Research Services. As with any mitochondrial-derived peptide, verification of purity and peptide identity should precede any experimental work; our guide to evaluating research peptide suppliers outlines the documentation to request. This information is provided as a research-availability reference only and is not a purchasing recommendation.
Frequently asked research questions
What is MOTS-c derived from?
MOTS-c is encoded within a short open reading frame in the 12S ribosomal RNA gene of mitochondrial DNA. This makes it a mitochondrial-derived peptide, distinct from the many signaling peptides encoded by the nuclear genome, and one of the first such peptides to be functionally characterized.
How is MOTS-c thought to work?
The leading mechanistic model holds that MOTS-c inhibits the folate cycle, causing intracellular AICAR to accumulate. AICAR activates AMP-activated protein kinase (AMPK), a cellular energy sensor associated in preclinical models with increased glucose uptake and fatty-acid oxidation.
How does MOTS-c differ from humanin?
Both are mitochondrial-derived peptides, but MOTS-c (16 amino acids, 12S rRNA) is studied primarily for metabolic regulation, while humanin (24 amino acids, 16S rRNA) is investigated chiefly for cytoprotection and apoptosis modulation. They act through largely separate pathways.
Is there human clinical evidence for MOTS-c?
No completed human efficacy trials exist. Human data is limited to observational studies showing that endogenous MOTS-c levels rise after acute exercise. Therapeutic effects of administered MOTS-c have been reported only in animal and cell-based models.
Why is MOTS-c called an exercise mimetic?
The label reflects its activation of AMPK — the same energy-sensing pathway engaged during physical activity — and rodent studies reporting improved endurance. The term describes a research hypothesis, not an established human effect.
What quality checks matter when sourcing MOTS-c for research?
Purity by high-performance liquid chromatography, identity confirmation by mass spectrometry, and a batch-specific certificate of analysis are the core documents. Research-use-only labeling and transparent third-party testing distinguish credible suppliers from unverified sources.
Works cited
- Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;21(3):443–454. PMID: 25738459. doi:10.1016/j.cmet.2015.02.009
- Yang B, Yu Q, Chang B, et al. MOTS-c: a novel mitochondrial-derived peptide regulating muscle and bone metabolism. Frontiers in Physiology / related preclinical reviews. 2023. PMID: 37200834
- Kim KH, Son JM, Benayoun BA, Lee C. The mitochondrial-derived peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metabolism. 2018;28(3):516–524. doi:10.1016/j.cmet.2018.06.008
- Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021;12:470. doi:10.1038/s41467-020-20790-0
- Merry TL, Chan A, Woodhead JST, et al. Mitochondrial-derived peptides in energy metabolism. American Journal of Physiology–Endocrinology and Metabolism. 2020;319(4):E659–E666. doi:10.1152/ajpendo.00249.2020
Research-use-only disclaimer. All content on this page is provided strictly for research reference and educational purposes. It is not medical advice. The compounds discussed are not approved for human or veterinary use, and nothing here should be interpreted as guidance for administration, dosing, or treatment. Explore related compounds: Humanin · 5-Amino-1MQ · SS-31 (Elamipretide).